Silence Therapeutics plc

SLN
As of the close on Sep 25, 2026
Price
$11.18
Market cap
—
The company filed earlier annual reports as a foreign issuer, and its US listing is not confirmed to be one ordinary share
P/E (diluted TTM)
—
Per-share earnings are not available for each of the last four quarters
EPS (TTM)
—
Per-share earnings are not available for each of the last four quarters
Dividend yield
—
The company filed earlier annual reports as a foreign issuer, and its US listing is not confirmed to be one ordinary share

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Silence Therapeutics plc Makes Money

Follow each dollar of revenue through to what shareholders keep.

From revenue to net income

Pick a year or quarter. Each band's width is its dollar amount.

Source: Silence Therapeutics plc — 10-Q filed May 7, 2026

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Feb 13, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Reported 13F positions

Each row shows what a filer reported for one date, not a current position. The link opens that filing.

Filer Report date Shares Value Filing
ROYAL BANK OF CANADA 2026-03-31 16 Not shown SEC filing
MILLENNIUM MANAGEMENT LLC 2026-03-31 1,074,191 Not shown SEC filing
Qube Research & Technologies Ltd 2026-03-31 104,555 Not shown SEC filing
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2026-03-31 115,281 Not shown SEC filing
BOOTHBAY FUND MANAGEMENT, LLC 2026-03-31 209,088 Not shown SEC filing
Tetragon Partners GP Ltd 2026-03-31 630,161 Not shown SEC filing
XTX Topco Ltd 2026-03-31 106,002 Not shown SEC filing
RHUMBLINE ADVISERS 2026-03-31 13,935 Not shown SEC filing
Siren, L.L.C. 2026-03-31 2,911,438 Not shown SEC filing
GAMMA Investing LLC 2026-03-31 9,365 Not shown SEC filing
Nantahala Capital Management, LLC 2026-03-31 2,146,731 Not shown SEC filing
Mirae Asset Global Investments Co., Ltd. 2026-03-31 2,450 Not shown SEC filing
Nextech Invest, Ltd. 2026-03-31 952,400 Not shown SEC filing
UBS Group AG 2026-03-31 246,937 Not shown SEC filing
BlackRock, Inc. 2026-03-31 204,777 Not shown SEC filing
5AM Venture Management, LLC 2026-03-31 476,200 Not shown SEC filing
Steward Partners Investment Advisory, LLC 2026-03-31 100 Not shown SEC filing
SG Americas Securities, LLC 2026-03-31 286,698 Not shown SEC filing
BNP PARIBAS FINANCIAL MARKETS 2026-03-31 147,668 Not shown SEC filing
GREAT POINT PARTNERS LLC 2026-03-31 1,020,489 Not shown SEC filing
  • Each value is checked against Silence Therapeutics plc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
  • Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.

Filer report history

Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.

  • HSBC HOLDINGS PLC: 172,834 shares reported 2025-12-31; 122,834 shares reported 2026-03-31.
  • SIMPLEX TRADING, LLC: 3,991 shares reported 2025-12-31; 612 shares reported 2026-03-31.
  • SBI Securities Co., Ltd.: 28 shares reported 2025-12-31; 28 shares reported 2026-03-31.
  • Ikarian Capital, LLC: 865,784 shares reported 2025-12-31; 865,784 shares reported 2026-03-31.
  • MARSHALL WACE, LLP: 155,680 shares reported 2025-12-31; 169,616 shares reported 2026-03-31.
  • BANK OF AMERICA CORP /DE/: 2,966 shares reported 2025-12-31; 29,773 shares reported 2026-03-31.
  • JANE STREET GROUP, LLC: 29,168 shares reported 2025-12-31; 100,927 shares reported 2026-03-31.
  • Point72 Asset Management, L.P.: 114,070 shares reported 2025-12-31; 119,711 shares reported 2026-03-31.
  • ADAR1 Capital Management, LLC: 23,643 shares reported 2025-12-31; 172,157 shares reported 2026-03-31.
  • Redmile Group, LLC: 2,164,777 shares reported 2025-12-31; 2,164,777 shares reported 2026-03-31.
  • GEODE CAPITAL MANAGEMENT, LLC: 29,538 shares reported 2025-12-31; 29,538 shares reported 2026-03-31.
  • BARCLAYS PLC: 5,065 shares reported 2025-12-31; 2,937 shares reported 2026-03-31.

Showing the 12 most recent filer reports.

14 filers have only one report here.

Unusually large insider trades

Each trade is compared with the other insider trades of the same kind in the same security among Silence Therapeutics plc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.

  • 2025-05-13 · Griffiths Richard Ian (derivative): Larger than 55 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-05-06 · Griffiths Richard Ian (derivative): Larger than 57 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-05-05 · Griffiths Richard Ian (derivative): Larger than 57 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-04-28 · Griffiths Richard Ian (derivative): Larger than 56 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-04-21 · Griffiths Richard Ian (derivative): Larger than 57 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-03-31 · Griffiths Richard Ian (derivative): Larger than 57 of the 61 other insider purchases of American Depositary Shares on file. SEC filing
  • 2025-01-17 · Griffiths Richard Ian (derivative): Larger than all 61 other insider purchases of American Depositary Shares on file. SEC filing

Purchases & sales (open market or private)

SecurityCodePriceFiling
2025-10-27Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+2,000unknownSEC filing
2025-10-27Griffiths Richard Ian · 10% ownerAmerican Depositary SharesS — Open market or private sale+2,000unknownSEC filing
2025-08-03Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+20,000unknownSEC filing
2025-08-03Griffiths Richard Ian · 10% ownerAmerican Depositary SharesS — Open market or private sale+20,000unknownSEC filing
2025-08-01Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+4,034unknownSEC filing
2025-07-31Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+14,342unknownSEC filing
2025-07-30Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+8,923unknownSEC filing
2025-07-29Griffiths Richard Ian · 10% ownerAmerican Depositary SharesP — Open market or private purchase+14,559unknownSEC filing

Showing 8 of 12 rows

Grants, exercises, tax & gifts

SecurityCodeFiling
2026-01-02Lemus David · DirectorShare Option (Right to Buy)A — Grant, award, or other acquisition+90,000SEC filing
2026-01-02HELLUMS RHONDA LYNETTE · Chief Financial OfficerEmployee Share Option (Right to Buy)A — Grant, award, or other acquisition+375,000SEC filing
2026-01-02Romano Steven J. · EVP and Chief R&D OfficerEmployee Share Option (Right to Buy)A — Grant, award, or other acquisition+300,000SEC filing
2026-01-02MCINERNEY TIMOTHY · DirectorShare Option (Right to Buy)A — Grant, award, or other acquisition+90,000SEC filing
2026-01-02Ede-Golightly James · DirectorShare Option (Right to Buy)A — Grant, award, or other acquisition+90,000SEC filing
2025-12-22Ede-Golightly James · DirectorShare Option (Right to Buy)A — Grant, award, or other acquisition+90,000SEC filing
2025-12-18Ross Iain · Interim PEOEmployee Share Option (Right to Buy)A — Grant, award, or other acquisition+900,000SEC filing
2025-05-05MCINERNEY TIMOTHY · DirectorShare Option (Right to Buy)A — Grant, award, or other acquisition+48,000SEC filing

Showing 8 of 10 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.